Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
FEBS J. 2022 Jun;289(12):3416-3418. doi: 10.1111/febs.16399. Epub 2022 Feb 27.
Understanding how HAI-1 and HAI-2 regulate the epithelial serine protease matriptase may hold the key to curing epithelial-derived cancer. HAIs are serine protease inhibitors that inhibit matriptase and have a poorly understood effect on the presence of matriptase protein in cells. In this issue of The FEBS Journal, Yamashita et al. provide much-needed new insights into this effect, describing it as a 'chaperone-like function' of HAI-1. However, several observations suggest that matriptase folds correctly without HAIs and that HAIs are not chaperones. We introduce the concept of 'ally proteins' to categorize the poorly understood function of HAIs, distinguishing them from chaperones. Comment on: https://doi.org/10.1111/febs.16348.
了解 HAI-1 和 HAI-2 如何调节上皮丝氨酸蛋白酶 matriptase,可能是治愈上皮源性癌症的关键。HAIs 是丝氨酸蛋白酶抑制剂,可抑制 matriptase,但其对细胞中 matriptase 蛋白存在的影响尚不清楚。在本期《FEBS 杂志》上,Yamashita 等人提供了对此效应的急需的新见解,将其描述为 HAI-1 的“伴侣样功能”。然而,一些观察结果表明,matriptase 在没有 HAI 的情况下也能正确折叠,并且 HAI 不是伴侣蛋白。我们引入了“盟友蛋白”的概念来对 HAI 的功能进行分类,将其与伴侣蛋白区分开来。评论:https://doi.org/10.1111/febs.16348.